Exploring the Cutting-Edge Technologies Shaping the Future of Healthcare...
Exploring Cutting-Edge Trends and Key Players in the Dynamic Landscape of Medical Technology...
The field of medical devices is rapidly evolving, with companies around the world pushing the boundaries of innovation to enhance patient care and outcomes. As we step into 2024, let's explore the top 24 medical device companies that are poised to make a significant impact on the healthcare landscape....
Medical devices play a crucial role in modern healthcare, ranging from simple tools like thermometers to complex devices such as pacemakers and imaging equipment. Ensuring the safety and efficacy of these devices throughout their lifecycle is of paramount importance. ...
Company Committed to Support U.S. Health Care Needs...
Combining image clarity and advanced automated features, the V6 offers efficient, comprehensive imaging capabilities for daily ultrasound scanning needs...
New peripheral line draw solution delivers first and only compatibility with integrated catheters...
Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.527 billion during the third quarter of 2023, growing 11.2 percent on a reported basis, 11.1 percent on an operational1 basis and 10.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $505 million or $0.34 per share (EPS), compared to $174 million or $0.12 per share a year ago, and achieved adjusted3 EPS of $0.50 for...
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, announced the phase-one completion of the company’s first anonymized global dialysis dataset—coined the Apollo database project—the foundation of the company’s long-term AI aspirations. Intended to advance patient care quality and outcomes by making kidney disease care more personalized and precise, the database provides a highly sophisticated view into the clinical care provided ...
Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB...
![[L-R]: Ms. Vivien Tan, XP Business Manager, Siemens Healthineers ASEAN; Prof. Dr. dr. Lina Choridah, Sp.Rad (K), Chairwoman Indonesian Woman Imaging Society; Hendya Perbangkara, Head of Diagnostic Imaging, Siemens Healthineers Indonesia](/uploads/articles/l_r__ms_vivien_tan_xp_business_manager_siemens_healthineers_asean-24188.jpg)
